Lung Cancer Drug Tabrecta Approved By The FDA — New Hope For People With a Specific Biomarker

The FDA's approval of Tabrecta marks a historic step in treatment for patients battling aggressive lung cancer. Researchers say this is just the beginning.

Published May 7, 2020

NOW
PLAYING
PARP Inhibitor Niraparib Now FDA Approved For Front-Line Ovarian Cancer Treatment
NOW
PLAYING
New Hope For Later Stage Prostate Cancer Patients: The PARP Inhibitor Olaparib Approved By The FDA
NOW
PLAYING
A Great New Option For Multiple Myeloma Patients: Daratumumab Now Available As a Quick Shot, Replacing Long Infusions
NOW
PLAYING
Innovative New Drug Approved For Multiple Myeloma Is Being Tested For COVID-19 Treatment
NOW
PLAYING
What Lung Cancer Patients Should Know About Immunotherapy During Coronavirus
NOW
PLAYING
Allogeneic Stem-Cell Transplant for Intermediate Risk AML Patients
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.